Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)
2.5300
+0.6100 (31.77%)
NASDAQ · Last Trade: Nov 10th, 7:56 PM EST
Detailed Quote
Previous Close
1.920
Open
2.440
Bid
2.490
Ask
2.510
Day's Range
2.310 - 2.970
52 Week Range
0.5271 - 5.129
Volume
20,163,239
Market Cap
404.87M
PE Ratio (TTM)
-42.17
EPS (TTM)
-0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,293,285
Chart
About Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative treatments for gastrointestinal diseases and disorders. The company primarily centers its research efforts on the discovery and development of medications that target specific pathways involved in gut health, thereby aiming to improve the quality of life for patients suffering from various gastrointestinal conditions. Ironwood engages in both in-house drug development and collaborations, working to bring new therapies to market that address unmet medical needs in the field of gastroenterology. Read More
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown.
